Orange Book product · Generic (ANDA)
ALBENDAZOLE
ALBENDAZOLE
At a glance
Jan 26, 2021
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Jan 26, 2021
5 yr 6 mo ago
Today
Pharmaceutical detail
Active ingredient
ALBENDAZOLE
Strength
200MG
Dosage form
TABLET
Route
ORAL
TE code
AB
Application
ANDA 211034
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
Yes
Active-ingredient family
View full familyGeneric (ANDA) of ALBENDAZOLE
- 1996ALBENZABrand (NDA)
NDA 020666 · IMPAX LABS INC
- 2024ALBENDAZOLEGeneric (ANDA)
ANDA 215652 · ALEMBIC
- 2021ALBENDAZOLEGeneric (ANDA)
ANDA 213435 · MSN
- 2020ALBENDAZOLEGeneric (ANDA)
ANDA 211636 · CHARTWELL RX
- 2019ALBENDAZOLEGeneric (ANDA)
ANDA 208094 · ACTAVIS ELIZABETH
- 2019ALBENDAZOLEGeneric (ANDA)
ANDA 211117 · EDENBRIDGE PHARMS
- 2018ALBENDAZOLEGeneric (ANDA)
ANDA 208979 · ZYDUS PHARMS
- 2018ALBENDAZOLEGeneric (ANDA)
ANDA 210011 · STRIDES PHARMA
- 2018ALBENDAZOLEGeneric (ANDA)
ANDA 210434 · CIPLA LTD
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
